Human melanocortin 4 receptor (hMC4R) mutations with in vitro functional effects are responsible for 0 . 5-2 . 5% of severe obesity. Designing ligands that are able to counteract this in vitro-associated molecular defect is crucial to develop specific anti-obesity drugs in these genetically associated cases. We analyzed the in vitro effect of two novel melanocortin agonists, IRC-022493 and IRC-022511, on typical hMC4R mutations chosen based on the nature of their functional alterations, i.e. intracytoplasmic retention and/or reduced basal activity and/or reduced a-MSH potency. We assessed the in vitro ability of IRC-022493 and IRC-022511 to bind and activate hMC4R mutants. These mutations were found earlier in 11 obese French patients (median age (range) was 17 . 6 years (5 . . 0) and body mass index (BMI)-Z-score 4 . 2 S.D. (1 . 5-5 . 5). The MC4R agonists were responsible for a significant activation of mutated hMC4R depending on the functional characteristics of the mutations. Both agonists were able to activate mutated hMC4R with decreased a-MSH potency, associated with or without decreased basal activity, to the same extent than a-MSH in wild-type MC4R. This result suggests that those mutations would be the best targets for the MC4R agonists among MC4R mutation-bearing obese patients. No specific clinical phenotype was associated with the differential response to pharmacological agonists. We identified two novel melanocortin agonists that were able in vitro to efficiently activate mutated hMC4R with impaired endogenous agonist functional response. These results stimulate interest in the development of these drugs for hMC4R mutations-associated obesity.
Introduction
Melanocortin 4 receptor (MC4R) mutations are responsible for the most common genetic cause of human obesity (Farooqi 2008) . The discovery of human MC4R (hMC4R) mutations affecting the receptor function pointed out not only the predominant role of MC4R in body weight regulation (Mutch & Clement 2006) but also reinforced the interest in the development of MC4R agonist to control obesity (Mackenzie 2006) .
MC4R receptor encodes a G-protein-coupled receptor, which transduces signals by coupling to the heterotrimeric Gs protein and activating adenylate cyclase. Expressed in hypothalamic nuclei controlling food intake, MC4R
integrates an agonist (anorexigenic) signal provided by the pro-opiomelanocortin product, a-melanocyte stimulating hormone (a-MSH), and an antagonist (orexigenic) signal provided by the agouti-related peptide. The role of MC4R in energy balance was first demonstrated in mice (Huszar et al. 1997) ; MC4R invalidated mice develop severe obesity while heterozygous animals are less obese. MC4R activation both by natural and pharmacological agonists decreased food intake in rodents and improved their metabolic conditions (Fan et al. 1997) .
In humans, the frequency of hMC4R mutations with in vitro functional consequences is relatively high (0 . 5-6%) in obese adults and children of European and North America origins (Farooqi et al. 2000 , Vaisse et al. 2000 , Lubrano-Berthelier et al. 2006 , Calton et al. 2009 ), while it is significantly !1% in controls (0 . 1-0 . 6%) , Lubrano-Berthelier et al. 2006 , Stutzmann et al. 2008 . Individuals are mostly heterozygous carriers of mutated hMC4R with an autosomic dominant inheritance and variable penetrance and expressivity with age and generational influences (Stutzmann et al. 2008) . While different classifications have been proposed (Tao & Segaloff 2003 , Biebermann et al. 2006 , Lubrano-Berthelier et al. 2006 , Tan et al. 2009 ), the functional consequences of hMC4R mutations can be schematically divided into the following categories: nonfunctional truncated receptor (i.e. due to missense or frameshift mutations), intracellular retention, altered basal activity, and altered a-MSH stimulation. Synthetic ligands, from classical NDP-MSH peptides to the multiple tetrapeptides and small molecule MC4R agonists, have been tested in vitro with distinct improvement of hMC4R functional activity depending on both agonist potency and nature of the mutation (Ujjainwalla & Sebhat 2007 , Xiang et al. 2007 . Determining which of the hMC4R mutations might be pharmacologically rescued by newly developed MC4R agonists is a promising approach to identify potential patients who may benefit the most from such drug candidates. In this study, we describe the in vitro effects of two novel melanocortin agonists on a set of selected mutated hMC4R, representative of previously established mutation classes (Dubern et al. 2001 , Lubrano-Berthelier et al. 2006 .
Materials and Methods

hMC4R mutations
We studied the effect of IRC-022493 (Dong & Moreau 2007) and IRC-022511 (Dong et al. 2008) , two novel MC4R agonists, on 11 hMC4R mutations described earlier in obese adults and children (Dubern et al. 2001 , Lubrano-Berthelier et al. 2006 Fig. 1B) . The mutations were chosen among the various categories found in obese patients based on their known in vitro functional alterations such as intracytoplasmic retention (Pro299His and Ile102Ser) (class 1), reduced basal activity (Arg18Cys, Arg18His, Val50Met, and Gly231Ser) (class 2A), reduced a-MSH potency (Ser127Leu) (class 2B), or the association of both reduced basal activity and a-MSH potency (Arg305Trp, Ser58Cys, Ile102Thr, and Gly252Ser) (class 2C were shown earlier to reduce food intake and body weight gain in normal rats (Halem et al. 2006) and to improve obesity, hyperinsulinemia, and fatty liver disease in diet-induced obese mice (Kumar et al. 2009 ). a-MSH was purchased from Bachem (Weil am Rhein, Germany).
hMC4R cloning and expression
Wild-type and mutated hMC4R genes from genomic DNA were cloned into a pcDNA5/FRT/V5-His-TOPO expression vector. After transformation and selection of Escherichia coli, the transformant plasmids were extracted, and selected using the restriction enzyme EcoRI and sequenced to confirm the presence of the mutation. For each gene, one of the established transformants was amplified and purified following the manufacturer's conditions (TA expression kit, Invitrogen). CHO flip-in cells were stably cotransfected with hMC4R and pOG44 recombinase using the Flip-In system (Invitrogen) and effectene transfection reagent (Qiagen). Transfected cells were selected with hygromycin.
Binding to hMC4R
Membranes were obtained by sonication of CHO flip-in cells stably expressing wild-type or mutated hMC4R in 50 mM
Tris-HCl, pH 7 . 4, and centrifugation at 39 000 g for 10 min at 4 8C. The pellet was resuspended in the same buffer and centrifuged at 50 000 g for 10 min at 4 8C and membranes in the resulting pellet were stored at K80 8C. 125 I]-NDP-a-MSH was separated by filtration through GF/C glass fiber filter plates (Unifilter; PerkinElmer) presoaked with 0 . 1% (w/v) polyethylenimine, using PerkinElmer Filtermate harvester. Filters were washed three times with 50 mM Tris-HCl, pH 7 . 4, at 0-4 8C and assayed for radioactivity using PerkinElmer Topcount scintillation counter. Binding data were analyzed by computer-assisted nonlinear regression analysis (XL fit; IDBS, Guildford, UK).
Determination of intracellular cAMP
Intracellular cAMP levels were determined by an electrochemiluminescence (ECL) assay (Meso Scale Discovery (MSD), Gaithersburg, MD, USA). CHO flip-in cells stably expressing wild-type or mutated hMC4R were suspended in RMPI 1640 containing 0 . 5 mM isobutylmethylxanthine and 0 . 2% BSA. They were dispensed (30 000 cells/well) in 384-well Multi-Array plates (MSD) containing integrated carbon electrodes and coated with anti-cAMP antibody. Increasing concentrations of a-MSH, IRC-022493, or IRC-022511 were added and the cells were incubated for 6 h at 37 8C. Then, a lysis buffer (HEPES-buffered saline solution with MgCl 2 and Triton X-100, pH 7 . 3) containing 0 . 2% BSA and 2 . 5 nM TAG ruthenium-labeled cAMP (MSD) was added and the cells were incubated for 90 min at room temperature. At the end of the incubation period, a Tris-buffered solution containing an ECL co-reactant and Triton X-100, pH 7 . 8, was added and cAMP levels in cell lysates were immediately determined by ECL detection with a Sector Imager 6000 reader (MSD). Data were analyzed by computer-assisted nonlinear regression analysis (XL fit; IDBS). ); G T0, fasting glucose (mmol/l); Ins, fasting insulin (mU/ml); TG, triacylglycerol (mmol/l); TC, total cholesterol (mmol/l); the other mutations have been found recently in these French subjects.
Results
We first evaluated our in vitro system by confirming the functional consequences of each hMC4R mutation in their ability to bind (Table 1 ) and be activated (Table 2) by their natural agonist a-MSH. Figure 2A illustrates a-MSH-stimulated cAMP production for one hMC4R mutation in each functional category. When compared with our previously described in vitro system (Vaisse et al. 2000 , Lubrano-Berthelier et al. 2006 , the EC 50 of a-MSH was generally higher but the ratio between wild-type and each mutated receptor was conserved (data not shown). When a-MSH potency was decreased (class 2B and 2C mutations and Ile102Ser), the alteration was more pronounced in the receptor activation efficacy than binding affinity with the exception of Arg305Trp that only showed a reduced binding affinity (Tables 1 and 2 ). For most mutations, the number of [
125 I]-NDP-a-MSH binding sites (B max ) was between 23 and 106% of wild-type hMC4R (Table 1) . B max was correlated to the maximal stimulation observed with a-MSH (E max ). E max values were included between 38 and 111% of wild-type hMC4R (Table 2) . Two exceptions were noticed: Pro299His (class 1) whose complete absence of binding and stimulation by a-MSH was observed and, intriguingly, Arg305Trp that elicited B max and E max of 192 and 8% of wild-type hMC4R respectively. Taken together, these results being similar to previous ones (Vaisse et al. 2000 , Lubrano-Berthelier et al. 2003 , 2006 confidently allowed us to use this in vitro system to test the pharmaceutical agonists. We evaluated the ability of the two ligands (IRC-022493 and IRC-022511) to bind and activate the hMC4R mutants. Whatever the mutation, the maximal stimulation of cAMP production (E max ) obtained with IRC-022493 or IRC-022511 was similar to the level reached by a-MSH (Table 2) . However, IRC-022493 showed a 28-to 95-fold higher affinity for MC4R (Table 1 ) and a 15-to 120-fold increased potency in stimulating cAMP ( Both agonists revealed increased potencies as compared to a-MSH on either wild-type or the mutated hMC4R, but the relevance in terms of beneficial activation of MC4R depended on the functional consequences of each mutation. In the case of primary major altered binding and cAMP stimulation by a-MSH, i.e. for hMC4R mutations in class 2B (decreased a-MSH potency) and class 2C (decreased basal activity and a-MSH potency), both agonists were able to reach the stimulation level of the natural ligand in wild-type hMC4R, especially for the mutations Ser127Leu, Ser58Cys, Ile102Thr, and Gly252Ser (Table 2 ). Figure 2B shows the comparative stimulation of cAMP production induced by a-MSH, IRC-022493, and IRC-022511 in the Gly252Ser hMC4R mutation. For hMC4R mutations associated with a decreased basal activity (class 2A), we could not predict the response even if an increased MC4R stimulation capacity was observed. In the case of a major reduced membrane expression (class 1), the agonists may lead to an enhanced hMC4R activation when part of the receptors remains reachable to the ligands (Ile102Ser). Otherwise, no benefit can be provided by the agonists (Pro299His).
We examined whether a specific clinical phenotype would be associated with the presence of hMC4R mutations that might be preferentially targeted by the agonists. No significant difference for each clinical and metabolic phenotype (age, sex, BMI-Z-score, blood pressure, and metabolic parameters) was found between the subjects separated according to the in vitro response of hMC4R mutations to the agonists (data not shown).
Discussion
This work shows that novel melanocortin agonists, IRC-022493 and IRC-022511, are able to offset in vitro the impaired endogenous agonist response of class 2B and 2C mutated hMC4R to the level of a-MSH in wild-type receptor. In a recent study (Xiang et al. 2007) , distinct relative potencies versus a-MSH were observed for synthetic agonists depending on the mutated receptor as compared with wild-type hMC4R. In agreement with that work, differences in IRC-022493 and IRC-022511 potency depended on the mutation type, although in this study, the potency ratio of IRC-022493 or IRC-022511 versus a-MSH was unchanged in mutated hMC4R as compared to wild-type hMC4R. In case of primary intracellular retention (class 1), the pharmacological agonists can improve hMC4R stimulation only if the receptor remains accessible to the ligands (Ile102Ser). When the hMC4R mutation induces a reduced basal activity with normal responsiveness to a-MSH (class 2A), the physiological response to the agonists cannot be anticipated but undesired overstimulation of the receptor might not be excluded. The beneficial effects of IRC-022493 and IRC-022511 appear to be of marked interest for hMC4R mutations with decreased a-MSH response (class 2B and 2C) . hMC4R and the ligands. Except for Ser127Leu, they are positioned closer to the cytoplasmic side of the lipid bilayer and are likely to be involved in ligand-induced conformational changes important for G-protein-induced signal transduction events (Xiang et al. 2007) . Ser127Leu is located in the third transmembrane domain and was described to be an important residue for interacting with the endogenous melanocortin conserved His-Phe-Arg-Trp residues. Ser127 residue might be important for receptor local hydrogen bonding interactions that might shift the hMC4R from the inactive to the active conformation state on ligand binding (Xiang et al. 2007) .
Our results reinforce the importance of the functional characterization of hMC4R mutations to categorize the different classes of MC4R mutations, and thus identify mutation-bearing patients who might benefit the most from MC4R agonist therapy. Mutations with decreased endogenous a-MSH response appear to be the best candidate responders for IRC-022493 and IRC-022511. Moreover, no specific clinical phenotype permits the selection of patients, who could benefit from such pharmacological treatment. Most mutations are found at the heterozygous state and little is known about MC4R dimerization in vivo. In addition, previous studies showed no dominant negative effect for intracellular retained receptors (Ho & MacKenzie 1999 and only one hMC4R mutation was described to result in a dominant-negative effect (Biebermann et al. 2003) . Whether the pharmacological agonists could stimulate the mutated hMC4R without affecting the wildtype hMC4R protein remains to be explored. No significant differences in clinical and metabolic phenotype were found between the subjects separated according to the in vitro response of hMC4R mutations to the two novel agonists. However, the spread variability of plasma triacylglycerol (TG) observed in obese patients may be in accordance with studies showing the direct role of the central melanocortin system on peripheral lipid metabolism (Nogueiras et al. 2007) . Indeed, blockade of MC4R directly increases lipid uptake and TG synthesis in the periphery most likely through effects on autonomic outflow, inducing a decrease in plasma TG. Furthermore, it was demonstrated very recently that IRC-022493 improves hepatic steatosis reducing liver lipid and TG content in diet-induced obese mice (Kumar et al. 2009 ). Those data suggest that MC4R agonists may have a protective effect on lipid metabolism and especially TG synthesis.
In both preclinical and clinical studies, the role of the melanocortin system in penile erection, in modulation of the cardiovascular system, in inflammatory responses, and in pain processing has been described suggesting the risk of side effects when using melanocortin agonists (Adan et al. 2006 , Shadiack et al. 2007 ). However, a very recent clinical study showed the influence of a pharmacological agonist on blood pressure and underlined the interest of MC4R agonist administration to MC4R mutation carriers since they had lower blood pressure than MC4R wild-type carriers (Greenfield et al. 2009 ).
In conclusion, we have shown that in vitro functional classification of hMC4R mutations using pharmacological agonists is an attractive approach for identifying the most promising responders among the obese population of MC4R mutation-bearing patients. Using this strategy, we demonstrated that mutated hMC4R with impaired endogenous agonist functional response can be activated by IRC-022493 and IRC-022511, and might represent a valuable therapeutic target for these novel melanocortin agonists. This observation suggests an interest in the development of specific drugs in hMC4R mutationsassociated obesity. 
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